Oric Pharmaceuticals, Inc. (ORIC): restructuring charge — ORIC Pharma restructures, cuts 20% workforce, and extends cash runway to 2H 2028

Oric Pharmaceuticals, Inc.

Initiated strategic pipeline prioritization, eliminating discovery research and reducing workforce by ~20%; expects ~$1.9M one-time charge in Q3 2025.
Proforma cash and investments of $436.4M as of June 30, 2025, extending cash runway to 2H 2028 (previously 2H 2027).
Q2 2025 R&D expenses $30.5M (up from $28.9M), G&A expenses $8.5M (up from $7.1M); no revenue reported.
ORIC-944 Phase 1b data showed 59% PSA50 and 24% PSA90 responses; enozertinib (formerly ORIC-114) continues enrollment in NSCLC trials.

Key facts

Extracted from this filing and checked against the source text.

Restructurings & Charges SEC 8-K Item 2.05/2.06 confidence 0.9

Oric Pharmaceuticals, Inc. announced a restructuring with charges of approximately $1.9 million affecting discovery research group (approximately 20% workforce reduction).

Type: restructuring
Charge: approximately $1.9 million
Affected area: discovery research group
Headcount: approximately 20% workforce reduction

Exact text from the filing

On August 12, 2025, the Company initiated a strategic pipeline prioritization to focus operational and financial resources on the continued advancement of its two lead clinical programs, ORIC-944 and ORIC-114. This initiative will result in a substantial decrease in preclinical research, primarily from the elimination of the Company’s discovery research group. This will result in an approximately 20% workforce reduction and the Company expects to incur a one-time cost of approximately $1.9 million primarily related to termination benefits, including severance and healthcare-related benefits.

View on SEC.gov

Browse all restructurings & charges →

Oric Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-25-107313

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.